Ori-C101 GPC3 CAR-T for Liver Cancer: NMPA Clears First Global Confirmatory Phase II Trial in HCC

Why Late-Line HCC Is the Hardest Slot in Solid-Tumor Oncology

Hepatocellular carcinoma — the dominant form of primary liver cancer — is a global problem with a regional concentration. China alone accounts for roughly 410,000 new cases and 317,000 deaths per year, according to the most recent figures cited in the BEACON dataset. The disease is also a leading cause of cancer death across Southeast Asia (where chronic hepatitis B is endemic), parts of sub-Saharan Africa, and Egypt. Patients from any of these regions who present at a Chinese tertiary cancer center with advanced disease are not rare.

The clinical problem is that the standard treatment ladder is short. First-line is typically a tyrosine kinase inhibitor (sorafenib or lenvatinib — both oral drugs, taken daily, with manageable but real side effects including hand-foot syndrome and hypertension) or, in selected patients, the combination of the PD-L1 inhibitor atezolizumab with the VEGF inhibitor bevacizumab (the IMbrave150 regimen — the current standard-of-care first-line option in most Chinese cancer centers). Patients who progress on first-line can be moved to second-line options — regorafenib, cabozantinib, or the PD-1 inhibitor tislelizumab in some jurisdictions (each with single-digit-to-low-teens response rates) — but the response rates are in the single digits to low teens, and median overall survival at the second line has historically hovered around 10 to 11 months.

What happens after that is the gap Ori-C101 is trying to fill. Patients who have failed both an ICI and a TKI have, in clinical practice, very few remaining options. The 2026 ASCO BEACON dataset puts the historical second-line ORR in this exhausted population at "below 13%" — and that is in trials; in real-world practice, where many patients are too sick to qualify for second-line trials, the response rate is generally lower. Most patients at this stage transition to best supportive care. Median OS in published real-world cohorts drops into the 6-to-8-month range.

This is the population Oricell is going after. The BEACON study enrolled patients who had failed at least two prior lines, including both a TKI and an ICI. It is, by design, a late-line Phase I — and the ORR it produced (66.7% at the recommended Phase 2 dose) is materially above the historical benchmark in the same slot.

Why CAR-T Has Been So Hard in Liver Cancer

It is worth pausing on why this is genuinely unusual. CAR-T therapy — the modality that has transformed relapsed B-cell lymphomas and multiple myeloma over the last decade — has been structurally difficult to translate into solid tumors for two main reasons. First, the antigen problem: blood cancers express clean surface markers (CD19, BCMA) that are present on essentially all tumor cells and largely absent from healthy tissue. Solid tumors share their surface proteins with normal organs, so the same CAR that would attach a T-cell to a tumor cell will also attack healthy tissue. CAR-T drugs in solid tumors need a target that is enriched on the cancer — ideally, a tumor-specific antigen.

Second, the tumor microenvironment (TME) problem: solid tumors build a local immune-suppressive shield that turns incoming T-cells off before they can do meaningful damage. Even if the CAR-T cell finds the right antigen, it can be neutralized within the tumor by myeloid-derived suppressor cells, regulatory T-cells, checkpoint ligands, and metabolic hostility. The blood cancers that CAR-T treats are not protected this way — circulating tumor cells in blood or bone marrow are exposed to the engineered T-cells without an in-situ barrier.

GPC3 is one of the better antigen choices for HCC. It is a cell-surface glycophosphatidylinositol-anchored protein that is expressed in roughly 70-80% of HCC tumors and is largely absent from normal adult tissue (the developing liver expresses it briefly in utero, but adult hepatocytes do not). That makes it a cleaner target than, say, AFP (which is secreted, not surface-bound) or GPC3's neighboring antigens. Oricell is not the first group to try GPC3 CAR-T — but the BEACON data are the first to suggest the antigen hypothesis can clear the late-line efficacy bar in a randomized setting.

The BEACON Phase I Data, and What the Numbers Actually Show

The BEACON dataset that ASCO featured in June 2026 is an investigator-initiated and company-sponsored Phase I in 18 efficacy-evaluable patients with advanced, heavily pretreated HCC — every patient had already failed at least two prior lines, including both a TKI and an ICI. As of the April 3, 2026 data cut, the headline results are:

The 21.4-month median OS deserves emphasis. The historical comparator is roughly 10.6 months in patients receiving second-line therapy after sorafenib failure — the figure most often cited in recent meta-analyses. A doubling of median OS in a heavily pretreated, single-arm Phase I is the kind of signal that justifies a randomized confirmatory study. It is not a Phase III result, and it is not yet practice-changing on its own. But it is the strongest late-line HCC efficacy signal from any CAR-T product to date.

Speed and Durability — Two Things That Matter for Solid-Tumor Cell Therapy

Two details from the BEACON dataset are worth flagging because they speak to the engineering, not just the biology. The first is speed of response: 89% of the responders (a striking fraction — most CAR-T datasets in solid tumors report a much lower early-response rate) had already achieved an objective response by their first post-infusion assessment (typically 4 weeks after CAR-T infusion). CAR-T products in blood cancers can also show early responses, but solid tumors often need months to shrink. That Ori-C101 produced measurable responses in nearly nine of ten responders within the first scan window suggests the engineered T-cells are trafficking to the tumor and killing cancer cells quickly — which is also a safety consideration, because rapid tumor lysis can drive CRS.

The second is durability: the company disclosed one patient who achieved a partial response at first assessment, progressed to a complete response by month four, and remains in remission at 24 months. A second durable-responder signal was flagged separately in the 2021 ASCO poster dataset, where an early patient achieved partial response with target-lesion shrinkage from 155.45 mm to 6 mm (a 96.1% reduction) and AFP falling from over 80,000 ng/mL to 742 ng/mL. That patient survived nearly three years. The consistency between the 2021 IIT (investigator-initiated trial) and the 2026 registrational data is part of what gives Oricell's claim of being a first-in-class GPC3 CAR-T program some weight.

What's Inside Ori-C101: The "Three-in-One" Engineering

Oricell is not the only Chinese biotech working on solid-tumor CAR-T, but it has invested more visibly in the engineering story (a deliberate choice — the cell-therapy competitive bar in solid tumors is now set by platform credibility, not just individual asset data). The company's own framing is a "three-in-one" platform that addresses the three classic failure modes of solid-tumor CAR-T: antigen heterogeneity, immunosuppressive TME, and manufacturing scale. The three pillars are:

• Ori®Ab — antibody discovery: a library of up to 10¹¹ fully human single-chain variable fragment (scFv) and nanobody sequences, screened using a live-cell-based high-throughput strategy that specifically identifies antibodies that bind the native conformational form of the target on the tumor-cell surface. The point of native-conformation screening is to find binders that will engage GPC3 in the conformation it presents on a hepatocyte-derived tumor, not the denatured form that phage-display or peptide screens can sometimes select for.
• Ori®CAR — co-stimulatory design: a second-generation CAR construct with a co-stimulatory domain and additional engineering intended to resist TME-induced exhaustion. The details of the co-stimulatory domain are not fully disclosed in the public materials, but the company has signaled that the design choice is targeted at the PD-1 / TGF-β axis that dominates the HCC tumor microenvironment.
• Ori®PEM — manufacturing: a proprietary production process engineered to compress the autologous manufacturing window. CAR-T manufacturing traditionally takes 2 to 4 weeks from leukapheresis to release; compressing that window matters for late-line HCC patients, who often have rapidly progressing disease and cannot wait a month for cells.

The engineering details matter less for an international patient than the fact that the platform is structured. Patients considering Ori-C101 in a clinical-trial context do not need to know the co-stimulatory domain — they need to know that the company has thought through the three places solid-tumor CAR-T typically fails, and that the Phase I data show those failure modes were not triggered at the recommended Phase 2 dose.

What the Phase II Trial Will Look Like, and Who It Enrolls

The Phase II trial cleared on June 8, 2026 is structured as a prospective, randomized, open-label, multicenter registration study in patients with GPC3-positive advanced HCC who have failed two or more prior lines of therapy. A few details to flag for patients and families thinking about the international patient path:

• Design: randomized and open-label, meaning patients will be assigned to receive either Ori-C101 or a comparator treatment (the company has not yet disclosed the comparator). The randomized design is the regulatory requirement for a confirmatory trial in China.
• Patient population: GPC3-positive, advanced HCC, at least two prior lines of systemic therapy (typically a TKI and an ICI). Patients will need to have documented GPC3 expression on their tumor — usually by immunohistochemistry on archived or fresh tissue.
• Centers: multi-center, with the leading sites expected to be in Shanghai. The principal investigators and the full site list have not been published in the June 8 press release; that information is typically released when the trial posts on chinadrugtrials.org.cn or clinicaltrials.gov.
• Primary endpoint: likely overall survival or objective response rate; the company has not specified in the public materials which endpoint the NMPA agreed to as the registration endpoint.

For an international patient, the practical question is: can I enroll? CAR-T clinical trials in China have a mixed record on international patient enrollment. Some accept non-Chinese residents with a translated medical record and a sponsor agreement; others limit enrollment to Chinese citizens or residents with local social security (hukou-based). Patients interested in the Ori-C101 Phase II should ask the sponsor's clinical operations team (or a Chinese hospital international office) directly. The Hainan Boao Lecheng pathway — which allows certain unapproved therapies (including cell therapies) to be used in a regulated medical-tourism zone — is not the same as a clinical trial, but it is a related option for HCC patients who want Ori-C101 outside a trial context once the data are sufficiently mature. We covered the Hainan Boao Lecheng medical-tourism zone in detail in our June 3 coverage of the Lecheng pilot zone.

What This Means for International Liver-Cancer Patients

The headline implication is straightforward: an autologous CAR-T therapy for late-line HCC now has a clear regulatory path in China. For the substantial fraction of international HCC patients who come to Chinese hospitals — predominantly from Southeast Asia, the Middle East, North and sub-Saharan Africa, and Central Asia — the Ori-C101 Phase II is one more reason that Shanghai and Beijing are reasonable places to be evaluated for advanced liver cancer.

A few points worth making explicitly.

First, this is a clinical-trial product, not yet a commercial therapy. Ori-C101 is not on the market in China or anywhere else. The only way to access it today is through the BEACON study (which is closing to new enrollment — the company has flagged BEACON enrollment as full, with the data set locked at the April 3, 2026 cut) or, prospectively, through the confirmatory Phase II that just got cleared. Patients should not pay for Ori-C101 outside a clinical-trial context — and any clinic offering "Ori-C101 infusion" outside a registered trial should be treated as suspect.

Second, CAR-T for solid tumors is logistically different from CAR-T for blood cancers. The blood-cancer CAR-T path at Jiahui International Cancer Center in Shanghai (which we covered in our June 6 case of a Pakistani patient with relapsed lymphoma) is a defined clinical workflow: leukapheresis, manufacturing, lymphodepleting chemotherapy, infusion, monitoring for CRS and ICANS. The solid-tumor CAR-T workflow is similar in structure, but the toxicity profile is different — solid-tumor CAR-T trials have generally seen less neurotoxicity than CD19 CAR-T, but liver-specific toxicities (transaminitis, tumor inflammation) are a real concern, and the monitoring is correspondingly more careful. The CRS rate in BEACON was described as "manageable," but the on-site ICU support is a non-negotiable part of the protocol.

Third, cost is not yet public. Oricell has not disclosed what Ori-C101 will cost if and when it reaches commercial approval in China. As a benchmark, autologous CD19 CAR-T products in China are typically priced at roughly 30-50% below US list prices (which run in the $370,000-$530,000 range for the drug alone, before hospital and monitoring costs — figures that have come down meaningfully since 2017, with multiple Chinese products now approved at sub-$200,000 all-in pricing, but still out of reach for most self-pay international patients). Solid-tumor CAR-T is more complex to manufacture, so the cost differential may be smaller. International patients considering Ori-C101 in a trial context typically do not pay for the drug itself, but they do pay for hospital, monitoring, leukapheresis, and any bridging therapy.

Fourth, the disease biology matters more than the geography. Ori-C101 only works for GPC3-positive HCC. The biomarker test (GPC3 IHC on tumor tissue) is a prerequisite. Patients whose tumors do not express GPC3 — roughly 20-30% of HCC cases — are not candidates. The biopsy should be discussed with the treating oncologist before considering trial enrollment.

Shanghai's Cell-Therapy Corridor, and Where Ori-C101 Fits In

Oricell is a Shanghai-headquartered biotech, and the Phase II trial is expected to enroll primarily at Shanghai sites. This puts the Ori-C101 program into the same clinical corridor that already supports the Jiahui International Cancer Center, Fudan University Shanghai Cancer Center, Ruijin Hospital, and a handful of other Shanghai centers with active international patient offices.

The cell-therapy corridor's emergence is not accidental. Shanghai has been positioning itself as a regional cell-therapy hub for the better part of a decade — a strategy that combines academic medical centers with strong translational pipelines, biotechs with manufacturing capacity in the Zhangjiang High-Tech Park (a dedicated biomedical industrial zone with co-located CDMO capacity), and the Shanghai municipal government's interest in attracting international biomedical investment. The result is that an international patient evaluating CAR-T in Asia today has a denser concentration of solid-tumor CAR-T and TCR-T programs in Shanghai than in almost any other single city outside the United States.

For HCC specifically, the relevant comparison is the global pipeline. The major Western CAR-T programs in HCC (at AstraZeneca, Roche/Genentech, and a few academic centers — most targeting GPC3 or AFP) have lagged the Chinese programs in the GPC3 space — the antigen was identified in the early 2000s (notably by Dr. Mitchell Ho's group at the NIH, who first raised GPC3 as a CAR-T target for HCC — a research thread that took more than 20 years to produce a viable late-line clinical candidate), but the late-line clinical efficacy barrier has been a serious filter. The 66.7% ORR at RP2D from BEACON is the first GPC3 CAR-T dataset to clear that barrier in a meaningful way. If the confirmatory Phase II reproduces it, Ori-C101 would be the first-in-class GPC3 CAR-T globally — and the first CAR-T product for HCC globally, period — a meaningful milestone for the Shanghai cell-therapy ecosystem and for Oricell as a company.

What to Watch in the Next 6 to 12 Months

Three milestones will determine whether the Ori-C101 story is the durable turning point it currently appears to be.

Phase II first-patient-in. The earliest concrete marker will be when the confirmatory Phase II starts dosing. A randomized, multi-center trial of this scope typically takes 12-18 months to fully enroll, but the first patient dosed is the visible signal that the program is operationally real and not just a press release.

Comparator selection. The randomized Phase II needs a comparator arm. If the comparator is regorafenib or cabozantinib (the second-line TKIs — each with historical ORR under 10%) and Ori-C101 shows a meaningful OS or ORR advantage, the registration path in China is straightforward. If the comparator is atezolizumab plus bevacizumab (the IMbrave150 first-line regimen, which is increasingly the standard), the bar is higher — but the dataset would be much more clinically useful.

Real-world international patient access. The first international patient treated with Ori-C101 in a Shanghai trial center will be a notable event. International patient enrollment in Chinese CAR-T trials has been historically limited, but the BEACON data are strong enough that Oricell has a commercial incentive (a Western biotech licensing deal for solid-tumor CAR-T is significantly easier to negotiate when there is a clear path to NMPA registration, and Oricell already signaled global development ambitions in its April Series C) to make the trial accessible — and a Shanghai hospital with an established international patient office (such as Jiahui or Ruijin) has a structural advantage in handling the logistics.

Solid-tumor CAR-T competitors to watch. Oricell is not the only Chinese biotech with a solid-tumor CAR-T in active development. Carsgen, PersonGen, and a handful of others (including several that have not yet published in the West) have GPC3 or claudin18.2 programs in earlier stages. If the confirmatory Phase II generates a clear signal, expect the competitive field to consolidate around GPC3 — and expect the next round of deals (licensing, partnership, acquisition) to focus on GPC3 cell-therapy assets. The 2026 Oricell Series C (the $70M initial closing announced in April) was structured explicitly for global solid-tumor CAR-T development; the BEACON data are the validation that the bet made sense.

If You Are a Patient or Family Considering This

For a patient with late-line advanced HCC, the practical next steps have not changed much with the June 8 announcement — the announcement makes the future clearer, but it does not move the present. The present looks like this (in order of immediate action):

1. Confirm GPC3 status. If a tumor tissue block is available (from a prior biopsy or resection — both common at the time of HCC diagnosis), ask the treating oncologist to order GPC3 immunohistochemistry. This is a routine test in most major centers; in China, it is standard workup for advanced HCC.
2. Get a second opinion on the clinical-trial option. The Oricell trial will post on the Chinese clinical trial registry once the first site is activated. A Shanghai cancer center with an international office can advise on whether the trial is a fit and what the enrollment logistics would look like.
3. Consider the bridging therapy window. Patients with rapidly progressing disease cannot wait 4-6 weeks for trial enrollment and screening. Bridging therapy (typically a TKI such as lenvatinib, or a locoregional therapy such as TACE — transarterial chemoembolization, which can shrink or stabilize liver tumors while preserving liver function) is often used to hold the disease stable while enrollment happens.
4. Plan for the monitoring window. CAR-T in solid tumors requires a 2-4 week on-site monitoring period post-infusion for CRS, ICANS, and liver-specific toxicities (transaminitis, hyperbilirubinemia — both reversible with supportive care, but both require lab monitoring every 48-72 hours). International patients should plan for at least 4-6 weeks total in Shanghai, including pre-infusion workup.
5. Get financial clarity in writing. For trial enrollment, the drug itself is typically provided at no cost by the sponsor. Hospital charges, leukapheresis, bridging therapy, and post-infusion monitoring are usually billed to the patient (the figures vary widely by hospital — public centers tend to be 30-50% below private international hospital quotes for comparable work). Get a written estimate from the hospital's international office before committing.

The Phase II clearance is a signal — not a finished therapy. For the right patient, with the right biomarker, at the right time in their disease course, it may be the best late-line option currently in clinical development anywhere in the world. The June 8 announcement is the regulatory event that makes that option realistic to plan around.